ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Microbiome Labs Launches DigestMate, a 2-in-1 Digestive Enzyme and Probiotic Formula

By: Newsfile

Franklinton, North Carolina--(Newsfile Corp. - December 3, 2025) - Microbiome Labs, a leader in microbiome-based solutions, today announced the launch of DigestMate™, a 2-in-1 digestive enzyme and probiotic formula.

Digestive health challenges are on the rise in America, impacting millions of lives and driving demand for innovative solutions. According to recent data from the Centers for Disease Control and Prevention (CDC) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), an estimated 60 to 70 million Americans suffer from digestive diseases each year. These issues account for more than 35 million physician visits and nearly nine million emergency department visits annually, underscoring the significant burden on healthcare systems and quality of life.

DigestMate™ combines 14 broad-spectrum, acid-stable digestive enzymes with a clinically studied blend of spore-forming probiotics and probiotic yeast. This dual-action formula supports the complete breakdown of carbohydrates, fats, proteins, and complex fibers while promoting robust gut barrier function and microbial diversity.

Key strains include Bacillus subtilis HU58™, Bacillus coagulans (SC-208), and Saccharomyces boulardii (CNCM-I-1079), which help normalize immune responses and support short-chain fatty acid production. The enzyme complex features amylase, protease, lipase, lactase, cellulase, alpha-galactosidase, glucoamylase, xylanase, and additional specialized enzymes that aid in nutrient absorption and help reduce occasional digestive discomfort such as gas and bloating.

"This is a game-changing enzyme formula for the market and for health care practitioners," said Alicia Galvin, MEd, RD, LD, IFNCP, head of scientific affairs at Microbiome Labs. "The combination of probiotics and digestive enzymes is designed to provide broad digestive support by addressing both nutrient breakdown and gut absorption."

DigestMate™ became available to health care practitioners in May 2025 through Microbiome Labs' authorized practitioner network. Beginning Dec. 1, 2025, DigestMate™ is available on Amazon.

For more information about Microbiome Labs and its portfolio of microbiome-focused formulations, visit microbiomelabs.com.

###

About Microbiome Labs
Microbiome Labs, part of Novonesis OneHealth, provides innovative, research-based solutions that support the body's microbial ecosystem. With a focus on clinical application and practitioner partnerships, Microbiome Labs delivers evidence-informed products designed to support overall wellness.

Contact:
Ilissa Goldenberg
R Public Relations
Email: ilissa@rprfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276658

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.38
-2.04 (-0.87%)
AAPL  284.15
-2.04 (-0.71%)
AMD  217.60
+2.36 (1.10%)
BAC  54.09
+0.90 (1.69%)
GOOG  320.62
+4.60 (1.46%)
META  639.60
-7.50 (-1.16%)
MSFT  477.73
-12.27 (-2.50%)
NVDA  179.59
-1.87 (-1.03%)
ORCL  207.73
+6.63 (3.30%)
TSLA  446.74
+17.50 (4.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.